Skip to main content
Joanne Weidhaas, MD, Radiation Oncology, Los Angeles, CA

Joanne B Weidhaas MD PHD, MSM

Radiation Oncology•Los Angeles, CA

Professor, David Geffen School of Medicine at UCLA

Join to view full profile

  • 200 Medical Plaza, Suite B265Los Angeles, CA 90095

  • Phone+1 310-825-9775

  • Fax+1 310-825-9775

Dr. Weidhaas is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Weidhaas' full profileAlready have an account?

Summary

  • Dr. Joanne Weidhaas is a Los Angeles-based specialist in radiation oncology, affiliated with Ronald Reagan UCLA Medical Center as a Professor and Division Chief since 2014. She holds an MD/PhD from Tufts University School of Medicine and completed her residency at Memorial Sloan Kettering Cancer Center in 2004. She is the founder and chairperson of MiraKind and co-founder of MiraDx. Her research focuses on cancers such as breast, lung, and ovarian cancer, with numerous publications in the field. Dr. Weidhaas also leads clinical trials investigating genetics' role in cancer treatment and risk. Her contributions have earned her several awards, including the Yale Cancer Center Award and the Michael Fry Research Award as well as numerous R01s.

Education & Training

  • Stanford Graduate School of Business
    Stanford Graduate School of BusinessMS, Management, 2012 - 2013
  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterResidency, Radiation Oncology, 2000 - 2004
  • Steward Carney Hospital
    Steward Carney HospitalInternship, Internal Medicine, 1999 - 2000
  • Tufts Sackler School
    Tufts Sackler SchoolPhD, Molecular Biology and Microbiology, 1991 - 1999
  • Tufts University School of Medicine
    Tufts University School of MedicineClass of 1999

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2015 - 2027
  • CT State Medical License
    CT State Medical License 2004 - 2017
  • NY State Medical License
    NY State Medical License 2000 - 2006

Awards, Honors, & Recognition

  • Michael Fry Research Award 2009
  • Yale Cancer Center Award, “Most Influential Paper in the Field" 2009
  • Recognition of Clinical Excellence Award Yale School of Medicine, 2006

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • A let-7 microRNA-Binding Site Polymorphism in KRAS Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab M...  
    Saridaki Z, Weidhaas JB, Lenz HJ, Laurent-Puig P, Jacobs B, De Schutter J, De Roock W, Salzman DW, Zhang W, Yang D, Pilati C, Bouche O, Piessevaux H, Tejpar S, Clin Cancer Res, 9/1/2014
  • A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma  
    Chung CH, Lee JW, Slebos RJ, Howard JD, Perez J, Kang H, Fertig EJ, Considine M, Gilbert J, Murphy BA, Nallur S, Paranjape T, Jordan RC, Garcia J, Burtness B, Forastie..., Ann Oncol, 7/1/2014
  • Radiation therapy oncology group gynecologic oncology working group: comprehensive results  
    Gaffney DK, Jhingran A, Portelance L, Viswanathan A, Schefter T, Weidhaas J, Small W Jr, Int J Gynecol Cancer, 6/1/2014

Lectures

  • The KRAS-variant in Head and Neck Cancer as a Predictive Biomarker, results of RTOG 0522 
    6/1/2014
  • MicroRNAs in cancer risk, biology and treatment 
    4/1/2014
  • Yale Cancer Center Evening Oncology Series: Breast Cancer 
    Yale CME, New Haven, Connecticut - 1/17/2012

Press Mentions

  • MiraDx Announces New Research Conducted by UCLA and Other Academic Centers Presented at ASTRO 2025 That Confirms That Prostate Cancer Patients Identified as High-Risk with PROSTOX™ Ultra for SBRT Toxicity Can Safely Receive Other Radiation Regimens
    MiraDx Announces New Research Conducted by UCLA and Other Academic Centers Presented at ASTRO 2025 That Confirms That Prostate Cancer Patients Identified as High-Risk with PROSTOX™ Ultra for SBRT Toxicity Can Safely Receive Other Radiation RegimensSeptember 29th, 2025
  • MiraDx Announces New Research Conducted in Collaboration with UCLA and Accepted for Presentation at ASCO 2025 That Highlights the Role of MicroRNA-Based Genetic Signatures in Predicting Radiation and Immunotherapy Treatment-Related Outcomes
    MiraDx Announces New Research Conducted in Collaboration with UCLA and Accepted for Presentation at ASCO 2025 That Highlights the Role of MicroRNA-Based Genetic Signatures in Predicting Radiation and Immunotherapy Treatment-Related OutcomesMay 23rd, 2025
  • MiraDx Announces New Study Published in Clinical Cancer Research Validating PROSTOX™ Ultra Diagnostic Test for Predicting Radiation-Induced Late Toxicity in Prostate Cancer
    MiraDx Announces New Study Published in Clinical Cancer Research Validating PROSTOX™ Ultra Diagnostic Test for Predicting Radiation-Induced Late Toxicity in Prostate CancerApril 7th, 2025

Grant Support

  • Germ-line miRNA binding site variants as biomarkers of toxicity and response to checkpoint inhibitionUNIVERSITY OF CALIFORNIA LOS ANGELES2019–2025
  • Let-7 Micrornas In Lung Cancer: Altering Growth And RadioresistanceNational Cancer Institute2009–2012
  • Defining The Genetic Basis Of The Radioresponse Using A C. Elegans Tissue ModelNational Cancer Institute2007–2011

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Joanne Weidhaas, Dr. Joanne Weidhaas, MD, Dr. J Weidhaas, Dr. Joanne B Weidhaas